Cancer drug trial halted early: what we know

NCT ID NCT05821777

Terminated Disease control Sponsor: Centessa Pharmaceuticals (UK) Limited Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times

Summary

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and see if the drug could shrink tumors. However, the trial was stopped early, so we have limited information on how well it worked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Institut Gustave Roussy

Villejuif, 94805, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
NEXT Oncology - Dallas

Irving, Texas, 75039, United States
Sarah Cannon Research Institute at Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Sarah Cannon Research Institute at HealthONE.

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute at Tennessee Oncology Nashville

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR